Replimune Group, which is developing oncolytic immunotherapies to fight solid tumors, announced terms for its IPO on Tuesday.
The Woburn, MA-based company plans to raise $101 million by offering 6.7 million shares at a price range of $14 to $16. Insiders intend to purchase $40 million worth of shares in the offering (40% of the deal). At the midpoint of the proposed range, Replimune Group would command a fully diluted market value of $500 million.
Replimune Group was founded in 2015 and plans to list on the Nasdaq under the symbol REPL. J.P. Morgan, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. It is expected to price during the week of July 16, 2018.
